Atlas Genetics

atlasgenetics.com

Atlas Genetics is creating a new category of in vitro diagnostics focused on decentralized, near-­patient and Point-­of-­Care (POC) testing for everyone. With routine testing rapidly moving from the “hub” to the “spokes,” Atlas’s io® platform is poised to benefit from this growing trend in decentralized testing. The company’s proprietary technology platform positions Atlas in the vanguard of the rapidly evolving and increasingly patient-directed landscape of consumer diagnostics, where convenience, rapid “test and treat,” and portability of platform are becoming critical to success. Atlas aims to meet patients where they are and improve patient outcomes by arming healthcare professionals with a simple-­to-­use, rapid and cost-­effective solution for on-­demand diagnosis of infectious diseases. A sample-answer time of 30 mins, high accuracy and low cost are hallmarks of the company’s broad platform for a broad range of infectious diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

COSMOSID® ENTERS MICROBIOME PARTNERSHIP WITH LOCUS BIOSCIENCES

CosmosID | June 22, 2022

news image

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. ...

Read More

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

news image

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More

Industrial Impact

AKILI ANNOUNCES PUBLIC COMPANY BOARD OF DIRECTOR NOMINEES

Akili Interactive | July 11, 2022

news image

Akili Interactive a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced the nominees for its future board of directors, effective upon the closing of Akili’s business combination with Social Capital Suvretta Holdings Corp. I subject to customary closing conditions. Shares of the new public company’s common stock are expected to trade on Nasdaq under the symbol “AKLI.” Akili’...

Read More

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

news image

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More
news image

Medical

COSMOSID® ENTERS MICROBIOME PARTNERSHIP WITH LOCUS BIOSCIENCES

CosmosID | June 22, 2022

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. ...

Read More
news image

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More
news image

Industrial Impact

AKILI ANNOUNCES PUBLIC COMPANY BOARD OF DIRECTOR NOMINEES

Akili Interactive | July 11, 2022

Akili Interactive a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, announced the nominees for its future board of directors, effective upon the closing of Akili’s business combination with Social Capital Suvretta Holdings Corp. I subject to customary closing conditions. Shares of the new public company’s common stock are expected to trade on Nasdaq under the symbol “AKLI.” Akili’...

Read More
news image

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us